Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Eliminated 229 Positions in Q2

NEW YORK (GenomeWeb News) – PerkinElmer reduced its headcount by 229 employees in the second quarter, the company disclosed in a document filed with the US Securities and Exchange Commission on Tuesday.

In its Form 10-Q, the firm said that the workforce reduction was made as part of a plan approved during the second quarter by management to realign operations, R&D resources, and production resources as a result of recent acquisitions. The firm has been quiet on the M&A front this year in the 'omics-related life science tools space, but during 2011 PerkinElmer made seven acquisitions, including its $600 million buy of Caliper Life Sciences.

As a result of the restructuring plan, PerkinElmer recognized a $4.0 million pretax restructuring charge in the Human Health segment, as well as a $200,000 pretax restructuring charge in the Environment Health segment, related to the headcount reduction from reorganization efforts.

It added that it expects to recognize an additional $5.4 million of incremental restructuring expense in "future periods."

The layoffs come on top of 243 positions that were eliminated by PerkinElmer during the first quarter of 2012 and fourth quarter of 2011 due to restructuring.

Other firms in the 'omics tools space have also recently implemented workforce reductions as they restructure their businesses. Thermo Fisher Scientific disclosed last week it eliminated 530 jobs in the first half of the year, and Roche is reducing its workforce by 120 positions as a result of the shutdown of its NimbleGen microarray business, as GenomeWeb Daily News' sister publication BioArray News recently reported.

Meanwhile, Complete Genomics and WaferGen also announced layoffs this year.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more